映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09606 映恩生物-B

已收盘 07-03 16:08:15

215.200

+6.000

+2.87%

最高226.000	最低208.600	成交量227.62万
今开210.000	昨收209.200	日振幅8.32%
总市值194.70亿	流通市值194.70亿	总股本9,048万
成交额4.92亿	换手率2.52%	流通股本9,048万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":215.2,"timestamp":1783066095010,"preClose":209.2,"halted":0,"volume":2276225,"delay":0,"changeRate":0.02868068833652008,"floatShares":90475100,"shares":90475100,"eps":-46.00039213840917,"marketStatus":"已收盘","change":6,"latestTime":"07-03 16:08:15","open":210,"high":226,"low":208.6,"amount":491624938,"amplitude":0.083174,"askPrice":215.2,"askSize":1300,"bidPrice":215,"bidSize":1800,"shortable":3,"etf":0,"ttmEps":-36.83729895063762,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":5,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":209.2,"openAndCloseTimeList":[[1783042200000,1783051200000],[1783054800000,1783065600000]],"volumeRatio":1.675195,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09606","defaultTab":"news","newsList":[{"id":"1180831978","title":"异动解读｜映恩生物-B盘中上涨6.31%，ADC赛道集中突破叠加科创板IPO受理催化延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1180831978","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180831978?lang=zh_cn&edition=full","pubTime":"2026-07-03 09:40","pubTimestamp":1783042855,"startTime":"0","endTime":"0","summary":"7月3日，映恩生物-B盘中上涨6.31%，报213.6港元/股，成交额9275.75万港元。消息面上，近期国产ADC赛道迎来集中突破，全球首款双抗ADC获批上市，中国企业领先优势显著；公司科创板IPO申请已获上交所受理，拟募资41亿元用于新药研发，双资本平台布局持续推进。行业层面，生物科技板块延续强势，三生制药涨4.85%，荣昌生物涨4.25%，康方生物涨2.69%，科伦博泰生物涨2.65%，信达生物涨2.4%，板块联动效应明显。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102162890","title":"异动解读｜映恩生物-B盘中上涨15.01%，ADC赛道迎集中突破叠加生物科技板块强势反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1102162890","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102162890?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:21","pubTimestamp":1782958881,"startTime":"0","endTime":"0","summary":"7月2日，映恩生物-B盘中上涨15.01%，报208.8港元/股，成交额2.09亿港元。消息面上，近期国产ADC赛道迎来集中突破，全球首款双抗ADC获批上市，中国企业领先优势显著，映恩生物科创板IPO申请已获上交所受理，拟募资41亿元用于新药研发，资本市场关注度提升。行业层面，生物科技板块今日整体走强，三生制药涨10.72%，康方生物涨8.74%，科伦博泰生物涨8.44%，信达生物涨8.04%，板块联动效应显著。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198082469","title":"异动解读｜映恩生物-B盘中上涨5.65%，回购护盘叠加生物科技板块反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1198082469","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198082469?lang=zh_cn&edition=full","pubTime":"2026-06-29 09:57","pubTimestamp":1782698221,"startTime":"0","endTime":"0","summary":"6月29日，映恩生物-B盘中上涨5.65%，报172.2港元/股，成交额2904.06万港元。消息面上，公司于6月26日斥资约1198.79万港元回购7.38万股，回购价介于161.2至164.4港元，显示管理层在股价低位积极护盘。此外，公司股东周年大会于6月26日通过新一轮回购授权，可回购股份总数达905.8万股，彰显对公司内在价值的信心。行业层面，生物科技板块今日整体回暖，药捷安康-B涨20.11%，荣昌生物涨6.25%，康方生物涨4.2%，百济神州涨1.63%，信达生物涨2.4%，板块联动效应明显。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647341995","title":"映恩生物-B(09606)6月26日斥资1198.79万港元回购7.38万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647341995","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647341995?lang=zh_cn&edition=full","pubTime":"2026-06-29 08:36","pubTimestamp":1782693366,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，该公司于2026年6月26日斥资1198.79万港元回购7.38万股股份，每股回购价格为161.2-164.4港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000500386.USD","HK0000252160.HKD","09606","LU2543165471.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186149461","title":"映恩生物-B：6月26日回购73,800股，耗资约1,198.79万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186149461","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186149461?lang=zh_cn&edition=full","pubTime":"2026-06-29 08:21","pubTimestamp":1782692514,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年6月29日发布公告，披露于2026年6月26日于香港联交所场内回购73,800股普通股，占当日前已发行股本总数约0.0815%。本次回购价格介乎每股161.20港元至164.40港元，总金额约11,987,880港元。回购完成后，公司已发行股本总数维持在90,875,214股，库藏股数量增至400,100股。公告还显示，购回授权的决议于2026年6月26日获得通过，授权可回购的股份总数为9,058,021股。本次回购符合香港联合交易所有限公司证券上市规则等相关法律法规的要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B：6月26日回购73,800股，耗资约1,198.79万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646736531","title":"映恩生物-B(09606.HK)：梁志杰已获委任为联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2646736531","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646736531?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:26","pubTimestamp":1782484010,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09606","HK0000252160.HKD","HK0000500386.USD","BK1161","HK0000252152.HKD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646365310","title":"映恩生物-B(09606)：梁志杰已获委任为联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2646365310","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646365310?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:26","pubTimestamp":1782484010,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，曾颖雯女士(曾女士)已辞任本公司的联席公司秘书(联席公司秘书)、香港联合交易所有限公司(联交所)证券上市规则(上市规则)第3.05条项下的本公司授权代表(授权代表)及根据上市规则第19.05(2)条及《公司条例》(香港法例第622章)第16部所规定于香港代表本公司接收法律程序文件及通知之获授权代表(法律程序代理人)职务，自2026年6月26日起生效。梁志杰先生(梁先生)已获委任为联席公司秘书、授权代表及法律程序代理人以接替曾女士，自2026年6月26日起生效。袁佳丽女士(袁女士)将继续担任另一名联席公司秘书。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09606","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646631833","title":"映恩生物-B(09606.HK)授出28.35万份限制性股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2646631833","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646631833?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:16","pubTimestamp":1782483401,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000252152.HKD","HK0000500386.USD","LU2543165471.USD","HK0000252160.HKD","09606","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154088157","title":"异动解读｜映恩生物-B盘中下跌5.18%，报159.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154088157","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154088157?lang=zh_cn&edition=full","pubTime":"2026-06-26 11:18","pubTimestamp":1782443924,"startTime":"0","endTime":"0","summary":"6月26日，映恩生物-B盘中下跌5.18%，报159.4港元/股，成交额4737.88万港元。映恩生物-B所在的生物科技行业中，板块整体承压，个股中，康方生物跌5.03%，信达生物跌2.3%，百济神州跌0.54%，三生制药跌0.93%，荣昌生物跌1.86%。映恩生物是一家主要从事临床阶段生物制药的投资控股公司，致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物，主要候选药物包括DB-1303/BNT323、DB-1311/BNT324等，公司主要在国内和国外市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643940763","title":"映恩生物-B(09606)6月16日斥资977.49万港元回购5.39万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643940763","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643940763?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:27","pubTimestamp":1781620025,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，于2026年6月16日斥资977.49万港元回购5.39万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","BK1161","LU2543165471.USD","HK0000252152.HKD","HK0000252160.HKD","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642299848","title":"映恩生物-B(09606)：上交所受理人民币股份发行申请材料","url":"https://stock-news.laohu8.com/highlight/detail?id=2642299848","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642299848?lang=zh_cn&edition=full","pubTime":"2026-06-12 22:30","pubTimestamp":1781274625,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，公司已向上海证券交易所提交有关人民币股份发行的申请材料，其中包括首次公开发行人民币普通股(A股)并在科创板上市招股说明书(申报稿)，并已于近期收到上海证券交易所就公司提交的人民币股份发行申请出具的受理单。A股招股说明书将刊载于上海证券交易所网站(http://www.sse.com.cn)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MCNHmain","BK1161","MUCmain","LU2543165471.USD","HK0000252152.HKD","HK0000500386.USD","UCmain","09606","CNHmain","CYB","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121144905","title":"异动解读｜映恩生物-B盘中下跌5.61%，生物科技板块集体承压回购难挡抛售潮","url":"https://stock-news.laohu8.com/highlight/detail?id=1121144905","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121144905?lang=zh_cn&edition=full","pubTime":"2026-06-11 10:36","pubTimestamp":1781145365,"startTime":"0","endTime":"0","summary":"6月11日，映恩生物-B盘中下跌5.61%，报166.6港元/股，成交额3620.53万港元。消息面上，公司虽于6月10日公告科创板IPO辅导通过上海证监局验收，并持续实施回购，但未能扭转股价颓势。此前公司凭借ASCO临床数据催化于6月5日一度反弹逾6%，但反弹昙花一现，股价自高点持续回落。生物科技板块今日集体走弱，百济神州跌5.71%、科伦博泰生物跌4.68%、康方生物跌4.43%、三生制药跌3.82%、信达生物跌3.09%，板块系统性抛压加剧个股调整。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158692458","title":"映恩生物-B于6月10日回购1万股，涉资约167.42万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1158692458","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158692458?lang=zh_cn&edition=full","pubTime":"2026-06-10 22:16","pubTimestamp":1781101013,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年6月10日发布翌日披露报表。公告显示，公司于2026年6月8日至6月10日期间因非董事人员根据首次公开发行前股权激励计划行使购股权，累计发行普通股32,300股，分别对应发行价格为每股178.0741港元、171.746港元及166.0608港元；此次新增发行股份总量合计占前次已发行股本约0.0357%。根据公告，截至2026年6月10日收市后，公司已发行股份总数为90,401,214股，库藏股数量为272,400股，合计已发行股份及库藏股数量为90,673,614股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"映恩生物-B于6月10日回购1万股，涉资约167.42万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642557424","title":"映恩生物-B(09606)6月10日斥资167.4万港元回购1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642557424","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642557424?lang=zh_cn&edition=full","pubTime":"2026-06-10 22:13","pubTimestamp":1781100818,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，于2026年6月10日斥资167.4万港元回购1万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452854.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","HK0000252152.HKD","BK1161","HK0000252160.HKD","09606","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642428704","title":"DualityBio Ltd.增持映恩生物-B(09606)1万股 每股作价173.778港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642428704","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642428704?lang=zh_cn&edition=full","pubTime":"2026-06-10 18:51","pubTimestamp":1781088687,"startTime":"0","endTime":"0","summary":"6月9日，DualityBio Ltd.增持映恩生物-B(09606)1万股，每股作价173.778港元，总金额为173.778万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260610/20260610185214_27442.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260610/20260610185214_27442.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452706.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["HK0000252160.HKD","LU2543165471.USD","HK0000500386.USD","HK0000252152.HKD","EWH","09606","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642413960","title":"映恩生物-B(09606.HK)：就建议人民币股份于科创板上市通过上海监管局辅导验收","url":"https://stock-news.laohu8.com/highlight/detail?id=2642413960","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642413960?lang=zh_cn&edition=full","pubTime":"2026-06-10 07:07","pubTimestamp":1781046422,"startTime":"0","endTime":"0","summary":"格隆汇6月10日丨映恩生物-B(09606.HK)发布公告，有关拟发行将于上交所科创板上市并以人民币买卖的普通股(“建议上市”)。公司现正接受中信证券的辅导，而公司已就有关辅导通过中国证监会上海监管局的验收。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260610/32274856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2543165471.USD","HK0000252160.HKD","09606","159982","HK0000500386.USD","CNHmain","MCNHmain","HK0000252152.HKD","BK1161","MUCmain","CYB","IPOS","UCmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150501392","title":"映恩生物-B获上海证监局辅导备案受理 拟推进人民币股份上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1150501392","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150501392?lang=zh_cn&edition=full","pubTime":"2026-06-10 06:22","pubTimestamp":1781043736,"startTime":"0","endTime":"0","summary":"映恩生物-B（Duality Biotherapeutics）已获得中国证监会上海监管局的辅导备案受理，此举标志着公司拟议的人民币股份上市计划迈出了关键一步。\n接受辅导备案是企业在境内资本市场进行首次公开募股前的必要程序。这意味着公司已正式启动上市辅导流程，将依照监管要求，在保荐机构的协助下，进行公司治理、财务规范等方面的完善工作，为后续提交上市申请做准备。\n此举被视为映恩生物-B拓展融资渠道、深化本土市场布局的重要战略举措。人民币股份上市若成功实施，将有助于公司进一步融入中国资本市场，为其生物医药技术的研发与商业化提供更充足的资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2543165471.USD","HK0000252160.HKD","09606","HK0000500386.USD","HK0000252152.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173838925","title":"异动解读｜映恩生物-B盘中下跌5.25%，ASCO反弹昙花一现回购力度难抵抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1173838925","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173838925?lang=zh_cn&edition=full","pubTime":"2026-06-08 11:25","pubTimestamp":1780889138,"startTime":"0","endTime":"0","summary":"6月8日，映恩生物-B盘中下跌5.25%，报176.8港元/股，成交额5288.32万港元。此前公司凭借连续回购及ASCO临床数据催化于6月5日一度反弹逾6%，但反弹未能延续。映恩生物是一家临床阶段生物制药公司，致力于研发抗体偶联药物创新药物，主要候选产品包括DB-1303/BNT323、DB-1311/BNT324等，用于靶向治疗多种实体瘤。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135490971","title":"映恩生物-B：6月5日回购7,000股并发行9,300股","url":"https://stock-news.laohu8.com/highlight/detail?id=1135490971","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135490971?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:52","pubTimestamp":1780660347,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年6月5日发布翌日披露报表，公告显示，公司于当日回购7,000股普通股，并将该等股份转为库存股份。此次回购股份占变动前已发行股份的0.0077%，每股价格介乎192.6港元至198.1港元，总金额1,372,080港元。本次变动后，映恩生物-B已发行股份增至90,378,914股，库存股份增至262,400股，总发行股份为90,641,314股。公司于2025年6月20日通过回购授权，可购回最多8,803,626股公司股份，截至目前累计回购股份数为262,400股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B：6月5日回购7,000股并发行9,300股","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641117008","title":"映恩生物-B(09606)6月5日斥资137.21万港元回购7000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641117008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641117008?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:45","pubTimestamp":1780659949,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，于2026年6月5日斥资137.21万港元回购7000股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","LU2543165471.USD","BK1161","HK0000500386.USD","HK0000252152.HKD","09606"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dualitybiologics.com","stockEarnings":[{"period":"1week","weight":0.2445},{"period":"1month","weight":0.0077},{"period":"3month","weight":-0.3535},{"period":"6month","weight":-0.2942},{"period":"1year","weight":-0.121},{"period":"ytd","weight":-0.2985}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":-0.1146},{"period":"3month","weight":-0.0821},{"period":"6month","weight":-0.1247},{"period":"1year","weight":-0.0482},{"period":"ytd","weight":-0.1005}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"映恩生物是一家主要从事临床阶段生物制药的投资控股公司。该公司致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物。该公司的主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310、DB-1305/BNT325、DB-1419和DB-2304。该公司的产品主要用于靶向治疗子宫内膜癌（EC）、乳腺癌（BC）、小细胞肺癌（SCLC）、去势抵抗性前列腺癌（CRPC）、食管鳞状细胞癌（ESCC）及头颈部鳞状细胞癌（HNSCC）。该公司主要在国内和国外市场开展业务。","exchange":"SEHK","name":"映恩生物-B","nameEN":"DUALITYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"映恩生物-B,09606,映恩生物-B股票,映恩生物-B股票老虎,映恩生物-B股票老虎国际,映恩生物-B行情,映恩生物-B股票行情,映恩生物-B股价,映恩生物-B股市,映恩生物-B股票价格,映恩生物-B股票交易,映恩生物-B股票购买,映恩生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}